TaiShang
ELITE MEMBER
- Joined
- Apr 30, 2014
- Messages
- 27,848
- Reaction score
- 70
- Country
- Location
Clinical human trials begin for COVID-19 vaccine in China
- Thread starter JSCh
- Start date
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
China Economy @CE_ChinaEconomy
China state-affiliated media
On Feb. 16, Brazilian Ministry of Health said it has signed a contract to purchase 54 mln doses of #COVID19 #vaccines produced by #China's Sinovac. Included 46 mln doses purchased by Butantan Institute, #Brazil has purchased a total of 100 mln doses of vaccines from Sinovac.
9:30 AM · Feb 20, 2021
China state-affiliated media
On Feb. 16, Brazilian Ministry of Health said it has signed a contract to purchase 54 mln doses of #COVID19 #vaccines produced by #China's Sinovac. Included 46 mln doses purchased by Butantan Institute, #Brazil has purchased a total of 100 mln doses of vaccines from Sinovac.
9:30 AM · Feb 20, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Global Times @globaltimesnews
China state-affiliated media
Latest facts about Chinese COVID-19 vaccine candidates: 1. 16 approved for clinical trials with six in Phase III trial; 2. 18 production lines established; 3. 43 million doses of the Sinopharm vaccine administrated worldwide with 34 million shots given in China.
11:10 AM · Feb 20, 2021
China state-affiliated media
Latest facts about Chinese COVID-19 vaccine candidates: 1. 16 approved for clinical trials with six in Phase III trial; 2. 18 production lines established; 3. 43 million doses of the Sinopharm vaccine administrated worldwide with 34 million shots given in China.
11:10 AM · Feb 20, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce
By Hu Yuwei
Published: Feb 23, 2021 08:43 PM
Sinopharm's COVID-19 vaccine. Photo: VCG
China's COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm's vaccine is the second protein subunit vaccine in the country after one developed by China's Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine is expected to perform better than the inactivated vaccines, and would be easier to mass produce, Sinopharm Chairman Liu Jingzhen suggested in a recent interview with China Central Television (CCTV).
Liu said its second COVID-19 inactivated vaccine - developed by subsidiary Wuhan Institute of Biological Products - is now applying for conditional approval for mass use.
China's first recombinant subunit COVID-19 vaccine, co-developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS), has been approved to enter phase III clinical trials in Pakistan.
The double-blinded, placebo-controlled trials will involve around 10,000 participants in Pakistan, of whom 30 percent will be seniors, according to news released by IMCAS on Sunday.
Experts said the recombinant subunit vaccine can be an important addition to the two Chinese inactivated vaccines already in mass production, considering its shorter production process.
"Traditional inactivated vaccines normally take several months to develop, and require biosafety level 3 labs for production. Meanwhile, access to the recombinant protein vaccine is easier, and the biotechnology is more mature than the mRNA and adenovirus-vector techniques used in some available vaccines," Zhuang Shilihe, a Guangzhou-based doctor closely studying the COVID-19 vaccines, told the Global Times on Tuesday.
Novavax, a US-based pharmaceutical company that developed a similar protein-based COVID-19 vaccine, reported an efficacy rate of 89.3 percent in its phase III clinical trials conducted in the UK in early February, boosting global confidence in this type of technical innovation.
Zhuang believes that protein subunit COVID-19 vaccines can perform better against new COVID-19 variants, as lab research found these new vaccines remain effective in triggering an immune response.
In a pre-print published on biology server BioRXIV on February 2, Gao Fu, director of the Chinese Center for Disease Control and Prevention, revealed that Zhifei's recombinant protein vaccine was still effective against the South African variant, although its efficacy was reduced by 1.6 times, which is within acceptable parameters. In particular, it was advantageous in comparison to the mRNA vaccine, leading with a reduction of three to eight times more.
Giving these promising signs, Uzbekistan's government has decided to purchase 1 million doses of Zhifei's vaccine and start voluntary mass vaccination, media reported.
Uzbekistan will almost double the number of volunteers from 5,000 to 9,000 involved in a phase III trial, the Uzbek Ministry of Innovative Development said in early February.
By Hu Yuwei
Published: Feb 23, 2021 08:43 PM
Sinopharm's COVID-19 vaccine. Photo: VCG
China's COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm's vaccine is the second protein subunit vaccine in the country after one developed by China's Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine is expected to perform better than the inactivated vaccines, and would be easier to mass produce, Sinopharm Chairman Liu Jingzhen suggested in a recent interview with China Central Television (CCTV).
Liu said its second COVID-19 inactivated vaccine - developed by subsidiary Wuhan Institute of Biological Products - is now applying for conditional approval for mass use.
China's first recombinant subunit COVID-19 vaccine, co-developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS), has been approved to enter phase III clinical trials in Pakistan.
The double-blinded, placebo-controlled trials will involve around 10,000 participants in Pakistan, of whom 30 percent will be seniors, according to news released by IMCAS on Sunday.
Experts said the recombinant subunit vaccine can be an important addition to the two Chinese inactivated vaccines already in mass production, considering its shorter production process.
"Traditional inactivated vaccines normally take several months to develop, and require biosafety level 3 labs for production. Meanwhile, access to the recombinant protein vaccine is easier, and the biotechnology is more mature than the mRNA and adenovirus-vector techniques used in some available vaccines," Zhuang Shilihe, a Guangzhou-based doctor closely studying the COVID-19 vaccines, told the Global Times on Tuesday.
Novavax, a US-based pharmaceutical company that developed a similar protein-based COVID-19 vaccine, reported an efficacy rate of 89.3 percent in its phase III clinical trials conducted in the UK in early February, boosting global confidence in this type of technical innovation.
Zhuang believes that protein subunit COVID-19 vaccines can perform better against new COVID-19 variants, as lab research found these new vaccines remain effective in triggering an immune response.
In a pre-print published on biology server BioRXIV on February 2, Gao Fu, director of the Chinese Center for Disease Control and Prevention, revealed that Zhifei's recombinant protein vaccine was still effective against the South African variant, although its efficacy was reduced by 1.6 times, which is within acceptable parameters. In particular, it was advantageous in comparison to the mRNA vaccine, leading with a reduction of three to eight times more.
Giving these promising signs, Uzbekistan's government has decided to purchase 1 million doses of Zhifei's vaccine and start voluntary mass vaccination, media reported.
Uzbekistan will almost double the number of volunteers from 5,000 to 9,000 involved in a phase III trial, the Uzbek Ministry of Innovative Development said in early February.
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
CGTN @CGTNOfficial
China state-affiliated media
#Iraq will purchase #COVID19 vaccines from China’s Sinopharm, the first vaccines allowed to enter the country, according to the prime minister's office on Tuesday. The first batch of vaccines will arrive in Iraq on March 1.
7:16 AM · Feb 24, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
CGTN @CGTNOfficial
China state-affiliated media
#Sinopharm's second COVID-19 vaccine has a 72.51% protection rate against the virus, an official statement said. Developed by the company’s Wuhan institute, it is in a race with #Cansino's adenovirus vector vaccine to become China's third vaccine to be granted market approval.
5:49 PM · Feb 24, 2021
China state-affiliated media
#Sinopharm's second COVID-19 vaccine has a 72.51% protection rate against the virus, an official statement said. Developed by the company’s Wuhan institute, it is in a race with #Cansino's adenovirus vector vaccine to become China's third vaccine to be granted market approval.
5:49 PM · Feb 24, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Nawal Al Kaabi @NawalAlKaabi
Sinopharm may offer immunity for up to six months but more research needed, top UAE official says https://thenationalnews.com/uae/health/sinopharm-may-offer-immunity-for-up-to-six-months-but-more-research-needed-top-uae-official-says-1.1173800… via @TheNationalNews
Sinopharm may offer immunity for up to six months but more research needed, top UAE official says https://thenationalnews.com/uae/health/sinopharm-may-offer-immunity-for-up-to-six-months-but-more-research-needed-top-uae-official-says-1.1173800… via @TheNationalNews
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
People's Daily, China @PDChina
China state-affiliated media
An adenovirus vector vaccine against #COVID19 by #CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said Chen Wei, a key scientist in the vaccine's development http://bit.ly/3uIbJGY
9:32 AM · Mar 1, 2021
China state-affiliated media
An adenovirus vector vaccine against #COVID19 by #CanSino Biologics is projected to provide protection for two years if a booster shot is administered, said Chen Wei, a key scientist in the vaccine's development http://bit.ly/3uIbJGY
9:32 AM · Mar 1, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Global Times @globaltimesnews
China state-affiliated media
China's single-dose #COVID19 #vaccine, the recombinant adenovirus vector vaccine produced by CanSino, takes as quick as one month to upgrade if the #coronavirus makes a critical mutation.
China state-affiliated media
China's single-dose #COVID19 #vaccine, the recombinant adenovirus vector vaccine produced by CanSino, takes as quick as one month to upgrade if the #coronavirus makes a critical mutation.
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
CGTN @CGTNOfficial18:49, 23-Dec-2020
Phase 3 trials of Chinese COVID-19 vaccine start in Uzbekistan
CGTN
People wearing face masks wait in line to enter the grocery store amid the COVID-19 outbreak in Tashkent, Uzbekistan April 9, 2020. /Reuters
Late-stage clinical trials of a Chinese candidate coronavirus vaccine has been carried out in Uzbekistan on Tuesday after early and mid-stage results suggest it is safe and efficient, researchers said.
The ZF2001 vaccine, which uses a harmless piece of the virus to induce the human body's immune response, is one of China's five candidate vaccines that have entered human trials overseas.
"We are planning to recruit 29,000 people globally," the Chinese Academy of Sciences (CAS) wrote in a statement, adding the late-stage trials started in China's Hunan Province in November and will soon be rolled out in Indonesia, Pakistan, and Ecuador.
The vaccine did not cause serious adverse effects, other than mild side-effects including injection pain, redness and swelling, according to a paper published on Tuesday before it was peer reviewed.
The combined data from Phase 1 and 2 trials involved 950 healthy Chinese participants aged 18-59. Low dose and high dose versions were tested. The Phase 2 study also tested two doses versus three doses for both the low dose and high dose versions.
The higher dose given via three injections spaced 30 days apart did not induce an improved immune response compared to the lower dose, the paper said. The Phase 3 trial will look at the lower dose version given over three injections, it said.
Neutralizing antibodies against the virus were detected among at least 93 percent of participants who received three shots in different groups. The levels of vaccine-triggered antibodies were higher than those seen in samples of patients recovered from the disease, researchers said.
However, these antibody-based readings are on their own not sufficient to predict how effective ZF2001 will be in protecting people from the virus, researchers said, warning they could not yet determine the duration of immune responses.
The vaccine also triggered moderate cell-based immune responses, a crucial part of the human immune system that works differently from antibodies.
Production for CAS' COVID-19 vaccine has been put into operation in September, according to vaccine manufacturer Anhui Zhifei Longcom Biopharmaceutical Co. The annual output is expected to reach more than 300 million doses, the company said.
Latest data shows over 76,315 people have been infected with the coronavirus in Uzbekistan. Cases peaked between July and September and so far have not spiked again.
(With input from Reuters)
China state-affiliated media
#Uzbekistan officially approved the registration of the #Chinese COVID-19 vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical, on Monday, according to the country’s authorities. The shot was undergoing phase 3 trials in the Central Asian nation.
7:36 AM · Mar 2, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Global Times @globaltimesnews
China state-affiliated media
Yin Weidong, CEO of Chinese #COVID19 #vaccine producer #Sinovac, said the company’s production capacity will be expanded to 2 billion doses per year by June.
11:36 AM · Mar 3, 2021
China state-affiliated media
Yin Weidong, CEO of Chinese #COVID19 #vaccine producer #Sinovac, said the company’s production capacity will be expanded to 2 billion doses per year by June.
11:36 AM · Mar 3, 2021
JSCh
ELITE MEMBER
- Joined
- Jun 9, 2011
- Messages
- 13,235
- Reaction score
- 2
- Country
- Location
Reuters Health @Reuters_Health
The COVID-19 vaccine developed by China's Sinovac Biotech has an efficacy of 83.5% based on final results of Phase III trials, Turkish researchers said on Wednesday, a downward revision from a preliminary finding of 91.25%.
The COVID-19 vaccine developed by China's Sinovac Biotech has an efficacy of 83.5% based on final results of Phase III trials, Turkish researchers said on Wednesday, a downward revision from a preliminary finding of 91.25%.
The COVID-19 vaccine developed by China's Sinovac Biotech has an efficacy of 83.5% based on final results of Phase III trials, Turkish researchers said on Wednesday, a downward revision from a...
7:15 PM · Mar 3, 2021Similar threads
